- Health Canada DPD: INNOHEP (LEO PHARMA INC, DIN 02358166) · product monograph (PDF)
- Spain CIMA (Spanish): search for “tinzaparin” (external search; text not reproduced)
Links only. These regulators' terms do not clearly permit reproducing the documents, so no text is shown here. Check the Philippine package insert in the products table.
Contraindications
- Current or past immune heparin-induced thrombocytopenia
- Active major bleeding or high bleeding risk
- Septic endocarditis
- Treatment doses with neuraxial anesthesia
- Hypersensitivity
Dosing: Adult
- Treatment of deep vein thrombosis and pulmonary embolism: 175 anti-Xa IU/kg SC once daily for at least 6 days and until oral anticoagulation is established
- Extended treatment of cancer-associated venous thromboembolism: 175 anti-Xa IU/kg SC once daily for 6 months; reassess beyond
- VTE prophylaxis, surgery: 3,500 IU SC 2 hours before surgery (moderate risk) or 4,500 IU 12 hours before (high risk), then once daily while at risk
- VTE prophylaxis, acute medical illness: 3,500 IU (moderate risk) or 4,500 IU (high risk) SC once daily while at risk
- Hemodialysis circuit: See the kidney panel
Dosing: Altered kidney function
Tinzaparin is a low-molecular-weight heparin cleared mainly by the kidneys but with significant non-renal elimination; the Irish label reports no accumulation down to creatinine clearance (CrCl) 20 mL/min. For venous thromboembolism treatment (175 IU/kg once daily) it is not recommended below CrCl 30 mL/min; if used, anti-factor Xa levels guide the dose. It has no current US FDA label.
Kidney function measure: Irish summary of product characteristics (SmPC) uses creatinine clearance (CrCl, mL/min).
Show full dosing details
- CrCl ≥60 mL/min
- Treatment: 175 anti-Xa IU/kg SC once daily (rounded in 1,000 IU steps) for at least 6 days and until oral anticoagulation is adequate; cancer-associated VTE: 6 months (SmPC).
- CrCl 30–59 mL/min
- No dose change at CrCl ≥30 (SmPC). No accumulation seen down to CrCl 20 in older adults.
- CrCl 15–29 mL/min
- Not recommended (dose not established). If needed and the benefit outweighs the risk, start with anti-factor Xa (anti-Xa) monitoring 4 to 6 hours after a dose and repeat after 3 to 4 doses (for guidance, 0.5 to 1.5 IU/mL in patients without severe impairment) (SmPC). In adults 70 years and older with kidney impairment, the IRIS trial stopped early for higher mortality with tinzaparin than unfractionated heparin (unexplained; anti-Xa did not accumulate); unfractionated heparin is a reasonable alternative.
- CrCl <15 mL/min (not on dialysis)
- Not recommended (dose not established). If needed and the benefit outweighs the risk, start with anti-factor Xa (anti-Xa) monitoring 4 to 6 hours after a dose and repeat after 3 to 4 doses (for guidance, 0.5 to 1.5 IU/mL in patients without severe impairment) (SmPC). In adults 70 years and older with kidney impairment, the IRIS trial stopped early for higher mortality with tinzaparin than unfractionated heparin (unexplained; anti-Xa did not accumulate); unfractionated heparin is a reasonable alternative.
- Hemodialysis (intermittent)
- Circuit anticoagulation (labeled): session of 4 hours or less, 2,000 to 2,500 anti-Xa IU as a bolus at the start of dialysis; session longer than 4 hours, 2,500 IU bolus then 750 IU/hour as a continuous infusion; adjust the bolus in 500 IU steps (usual 2,000 to 4,500 IU) (prophylaxis/hemodialysis SmPC). Treatment doses for VTE are not recommended (CrCl <30); if used, anti-Xa-guided. Half-life about 2.5 hours after an IV bolus in dialysis patients.
- Peritoneal dialysis
- Treatment doses not recommended (CrCl <30); if used, anti-Xa-guided.
- CRRT
- Not recommended at treatment doses; if used, anti-Xa-guided. Unfractionated heparin is usually preferred.
- Dialyzable? Not stated.
- Monitoring Anti-Xa (0.5 to 1.5 IU/mL 4 to 6 hours after dose) if used at CrCl <30. Platelets before and during treatment (heparin-induced thrombocytopenia). Potassium in diabetes, chronic kidney failure and metabolic acidosis (hypoaldosteronism). Neuraxial anesthesia timing (SmPC 4.2, 4.4).
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: HPRA (Ireland) product information (November 2024). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Not established under 18 years (SmPC).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Tinzaparin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
InnohepTinzaparin Sodium | 10000 anti-Xa IU/mL Solution For Injection (SC)2 mL colorless glass Type I vial with bromobutyl rubber stopper and aluminum cap (Box of 10's) | Rx | Leo Pharma A/SDenmark | Getz Bros. Philippines, Inc. | BR-1080 | Dec 12, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Antiplatelets, NSAIDs, thrombolytics, vitamin K antagonists, other anticoagulants | Adjust or monitor | More bleeding. | Avoid or monitor closely. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Bleeding
- Anemia
- Injection-site reactions
Serious
- Major hemorrhage
- Heparin-induced thrombocytopenia (immune)
- Spinal or epidural hematoma with neuraxial anesthesia
- Hyperkalemia (hypoaldosteronism)
- Anaphylaxis, skin necrosis, Stevens-Johnson syndrome
Monitoring parameters
- Anti-Xa (0.5 to 1.5 IU/mL 4 to 6 hours after dose) if used at CrCl <30. Platelets before and during treatment (heparin-induced thrombocytopenia). Potassium in diabetes, chronic kidney failure and metabolic acidosis (hypoaldosteronism). Neuraxial anesthesia timing (SmPC 4.2, 4.4). Kidney
- Platelets
- Potassium in at-risk patients
- Anti-Xa if CrCl <30
Pharmacokinetics
Key PK parameters
| Bioavailability | About 90% (SC) |
|---|---|
| Time to peak | 4 to 6 hours |
| Half-life | About 3.7 hours |
| Half-life in kidney failure (ESKD) kidney | About 2.5 hours after an IV bolus in dialysis patients; no accumulation down to CrCl 20 |
| Metabolism (CYP, transporters) | Minor hepatic depolymerization |
| Renal excretion kidney | Mainly renal (unchanged or nearly unchanged), with significant non-renal elimination |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Tinzaparin 10,000 anti-XA IU/mL, 0.45 mL pre-filled syringe | ₱238.31 | per syringe | DPRI reference price |
| Tinzaparin 10,000 anti-Xa IU/mL, 2 mL vial | ₱711.57 | per vial | DPRI reference price |
Reference price based on the Maximum Wholesale Price (MWP); excluded from the 10% inflation allowance
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Tinzaparin (as sodium) |
| PNF listing | Inj.: 10,000 anti-Xa IU/mL, 0.35 mL and 0.45 mL pre- filled syringe (SC)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 10,000 anti-Xa IU/mL, 2 mL vial (SC)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Health Products Regulatory Authority (Ireland). innohep 14,000 IU/0.7 mL SmPC (PA0046/060/011) [HPRA (Ireland) product information, November 2024; no US FDA label]. https://assets.hpra.ie/products/Human/13982/Licence_PA0046-060-011_22112024160300.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Leo Laboratories Limited. (2024). innohep 14,000 IU/0.7 mL solution for injection (tinzaparin sodium) [Summary of product characteristics, licence PA0046/060/011; text revised November 2024]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/13982/Licence_PA0046-060-011_22112024160300.pdf
- Leo Laboratories Limited. (2024). innohep 3,500 IU solution for injection (tinzaparin sodium) [Summary of product characteristics (prophylaxis and hemodialysis), licence PA0046/060/009; text revised November 2024]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/13980/Licence_PA0046-060-009_22112024160300.pdf
- Leizorovicz, A., Siguret, V., Mottier, D., & IRIS Investigators. (2011). Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep in Renal Insufficiency Study (IRIS). Thrombosis Research, 128(1), 27–34. https://doi.org/10.1016/j.thromres.2011.03.002
- Siguret, V., Gouin-Thibault, I., Pautas, E., & Leizorovicz, A. (2011). No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: The IRIS substudy. Journal of Thrombosis and Haemostasis, 9(10), 1966–1972. https://doi.org/10.1111/j.1538-7836.2011.04458.x
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .